Recent Posts
- Illinois Attorney General Files Lawsuit Against HIV/AIDS Nonprofit
- California Gov. Arnold Schwarzenegger Signs Budget That Cuts $52M From HIV/AIDS Programs
- Efforts Underway In Namibia To Treat Pediatric HIV
- HIV/AIDS Education Project Targeting Pennsylvania Black Women Examined
- Also In Global Health News: Uganda Male Circumcision; Malaria Vaccine; Potential Global Fund Grant In Cambodia; PMTCT Of HIV In Botswana
Random Posts
- Gilead Sciences, Tibotec To Develop Second Once-Daily HIV Treatment
- Baltimore Churches Participate In Program Providing HIV Testing To Residents
- Also In Global Health News: Children With HIV/AIDS; Leishmaniasis Treatment; ITNs In Tanzania; U.S. Malaria Fight; PEPFAR Safe Injection Funds
- Public Hearing Examines Issues Faced By Children In Thailand, Including HIV/AIDS, Lack Of Sex Education
- Young People At High HIV Risk Say Peers Should Teach Prevention
- FDA Marks 100th HIV/AIDS Drug Authorized For Purchase Under PEPFAR
- Also In Global Health News: Global Fund Audit; Indonesia's Health System; Bread For The World Founder Profiled
- First Engineered T Cell Receptor Trial Opens With New Cellular Therapy For HIV
- $17 Million To UC San Diego For Methamphetamine/AIDS Research
- New Epidemic Of Sexually Transmitted Hepatitis C Infection In HIV-infected Men In NYC
Prescription AIDS Drugs
Contact Us
Viewing An HIV Accomplice At An Atomic-Level
March 31st, 2010
Since the discovery in 2007 that a component of human semen called SEVI boosts infectivity of the virus that causes AIDS, researchers have been trying to learn more about SEVI and how it works, in hopes of thwarting its infection-promoting activity.
Now, scientists at the University of Michigan have determined the atomic-level, three-dimensional structure of a SEVI precursor known as PAP248-286 and discovered how it damages cell membranes to make them more vulnerable to infection with HIV. The work is described in two new papers. The most recent, describing the structure, was published online Nov. 17 in the Journal of the American Chemical Society. The paper describing how PAP248-286 interacts with cell membranes appeared in the Nov. 4 issue of Biophysical Journal.
PAP248-286 is a peptide—a chain of amino acids not long enough to be considered a protein. Individual PAP248-286 peptides have a tendency to clump together to form amyloid fibers called SEVI (semen enhancer of viral infection). Amyloid fibers are of great interest because they are the calling cards of many neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, and aging-related diseases like type-2 diabetes. Using NMR (nuclear magnetic resonance) spectroscopy, a technique that not only yields atomic-level details of a molecule’s structure, but also shows how the molecule nestles into the membrane with which it interacts, researcher Ayyalusamy Ramamoorthy and coworkers found that the structure of PAP248-286 is unlike that of most other amyloid-forming peptides and proteins.
In solution, SEVI is completely unstructured or has no definite shape and is therefore ineffective. On the other hand, “when bound to the membrane, it’s in a spaghetti-like arrangement—a disorganized, loose coil,” said Ramamoorthy, a professor of chemistry and of biophysics. In contrast, most other amyloid proteins assume a more ordered, helical configuration. Also unlike other amyloid peptides, SEVI does not penetrate deep into the greasy region of the cell membrane, but is located near the surface. Ramamoorthy and coauthors believe the spread-out, disordered configuration and its location in the cell membrane may explain the ability of SEVI fibers to enhance HIV infection, as the arrangement provides more surface area with which the virus can interact.
A key finding of the second study is that PAP248-286 “shocks” the membrane, inducing a structural change—a kind of dimple that allows HIV to attach to and enter the cell.
Next, Ramamoorthy and colleagues hope to discern more structural details of PAP248-286 and SEVI. They also plan to screen antioxidant compounds such as green tea extract, curcumin and resveratrol (found in red wine) to see if such compounds are capable of blocking SEVI’s HIV-enhancing activity.
Ramamoorthy’s coauthors on the Journal of the American Chemical Society paper are graduate student Ravi Nanga, post-doctoral fellows Jeffrey Brender and Nataliya Popovych and NMR specialist Subramanian Vivekanandan. His coauthors on the Biophysical Journal paper are Brender, graduate student Kevin Hartman, former post-doctoral fellow Lindsey Gottler, former graduate student Marchello Cavitt and biophysics undergraduate student Daniel Youngstrom.
This research was supported by funds from the National Institutes of Health.
Source: Nancy Ross-Flanigan
University of Michigan
Related posts:
- ‘Hijacking Mechanism’ Of HIV-1′ Pinpointed By McGill/JGH Researchers Researchers at McGill University and the affiliated Lady Davis Institute...
- Potential For Creating Less Toxic Anti-HIV Drugs Following Discovery Of Enzyme Structure By discovering the atomic structure of a key human enzyme,...
- Binding Action Of 2 Key HIV Antibodies Could Lead To New Vaccine Design A very close and detailed study of how the most...
- New View Of HIV Entry May Lead To Next Generation Of Inhibitors Scientists may need to rethink the design of drugs meant...
- Current Multi-Omponent Vaccines May Need Reworking, According To Study Current strategies for designing vaccines against HIV and cancers, for...
Related posts brought to you by Yet Another Related Posts Plugin.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.





